Literature DB >> 3974702

Interferon amplifies complement activation by Burkitt's lymphoma cells.

E Yefenof, I McConnell.   

Abstract

Interferon was originally described as an antiviral agent produced shortly after onset of infection with most viruses. However, in addition to inducing an antiviral state, interferon inhibits cell division, increases the expression of cell-surface antigens, boosts the cytotoxic activity of natural killer (NK) cells and modulates several immune functions of lymphocytes and macrophages. Moreover, a special class of interferon (immune interferon or IFN-gamma) is produced by T cells following stimulation with antigen or interaction with mitogens. The different methods by which interferon is induced and its multiple effects suggest that it may be part of a first-line defence system controlling the spread of virus infections and the proliferation of modified 'self' cells that have been affected by virus infection or neoplastic transformation. The ability of certain human lymphoma cells to activate the alternative pathway of complement is well established. Here we show that monoclonal antibody-purified interferon can amplify the ability of certain tumour cells to activate complement via the alternative pathway. This demonstration may reflect an additional, as yet unknown, role of interferon in inducing non-specific anti-tumour immunity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3974702     DOI: 10.1038/313684a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  2 in total

1.  Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46).

Authors:  T Seya; T Hara; M Matsumoto; Y Sugita; H Akedo
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

2.  Purification and characterization of a human membrane protein that activates the alternative complement pathway and allows the deposition of homologous complement C3.

Authors:  M Matsumoto; F Yamashita; K Iida; M Tomita; T Seya
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.